HUPO taps Invitrogen in proteomic standard initiative

HUPO and Invitrogen collaborate to develop new proteomic standards, products and processes.

Chris Anderson
MONTREAL—The Human Proteome Organization (HUPO) and Invitrogen announced last month a sci­entific collaboration where­by Invitrogen scientists will support efforts by HUPO to develop new proteomic standards, products and processes. The announce­ment marks the first of what may be a number of collabo­rations between HUPO and other for-profit companies as it pushes forward with a number of different stan­dards creation initiatives.
 
For Invitrogen, being tapped by HUPO for this project is a feather in its cap in terms of validating its ever-strengthening position in the proteomics market, as well as a way to foster broader work in the pro­teomics field.
 
"We want to be partners with HUPO in advanc­ing proteomic research to make sure that scientists can build upon the work of others scientists for the col­lective information and the value of studying the human proteome can be assembled more quickly and the results can be interpreted more accurately," says Chuck Piazza, VP of pro­teomics with Invitrogen.
 
It's not an easy problem to tack­le, Piazza notes, since everyday proteomic research methods, such as 2D electrophoresis, are very hard to standardize. The idea is to attempt to drive some form of pro­teome-scale standards and to find ways to provide known standard sets to research laboratories that are looking to contribute data, so that data sets can be compared.
 
It's important to note, Piazza says, that Invitrogen is in no way looking to drive HUPO in a par­ticular direction regarding stan­dards, rather it is taking direction from HUPO on what it and its member scientists see as the most effective method for achieving the optimal solution.
 
Under the direction of HUPO, Invitrogen will leverage many of its internal resources including fluorescence imaging and protein labeling to provide technical assis­tance during the process.
 
For HUPO, the collaboration with Invitrogen comes roughly nine months after it embarked on a course of addressing test protein standards. According to John J. M. Bergeron, president of HUPO, work with Invitrogen began shortly thereafter to ensure that Invitrogen-supplied proteins would meet the criteria and were of very high purity.
 
"In short, we wanted these to represent the kinds of proteins that the proteomics community would be interested in characterizing as their first step," Bergeron says.
 
Currently, he notes, there are two protein standards that come from a mix of roughly 100 proteins which are being used to benchmark dif­ferent proteomic platforms.
 
"This is not a competition," Bergeron says. "The objective here is for us to use our education and training committee to ensure that proteomics in the HUPO commu­nity is reaching the very top stan­dards currently attainable. We will then work with the community and our industrial partners in order to make the analytical tools more accessible, more reproducible and as error-free as possible, so that we can get a complete, accurate repre­sentation of the observations."
 
Invitrogen will aid with the test protein standard by ramping up the number of proteins available to 200 within the first year and as many 1,000 to 1,500 within two years.
 
Working with a company like Invitrogen on this project has a cou­ple of very real benefits to HUPO, Bergeron notes. "Companies like Invitrogen have an unbelievable level of quality control to ensure the quality of the protein that is being made," he says. "It is also part of the way we are looking at moving forward which is to encourage the private sector to cooperate with the public sector to make sure that the field can advance in a productive manner."

Chris Anderson

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Front Cover

Latest Issue  

• Volume 18 • Issue 12 • December 2022/January 2023

December 2022/January 2023

December 2022/January 2023 issue